PMID- 19247821
OWN - NLM
STAT- MEDLINE
DCOM- 20090910
LR  - 20211020
IS  - 1573-2592 (Electronic)
IS  - 0271-9142 (Linking)
VI  - 29
IP  - 4
DP  - 2009 Jul
TI  - Influence of HLA-DRB1 alleles on antibody responses to PfCP-2.9-immunized and 
      naturally infected individuals.
PG  - 454-60
LID - 10.1007/s10875-009-9281-0 [doi]
AB  - INTRODUCTION: The Plasmodium falciparum chimeric protein, PfCP-2.9, which 
      consists of apical membrane antigen (AMA)-1(III) and merozoite surface protein 
      (MSP)1-19, is a promising asexual-stage malaria vaccine currently being evaluated 
      in clinical trials. This study attempts to investigate the potential association 
      between human leukocyte antigen (HLA)-DRB1 genotype and antibody response against 
      PfCP-2.9 in healthy population and malaria patients. MATERIALS AND METHODS: We 
      investigated the HLA-DRB1 alleles in 40 participants from phase I trial and 86 
      malaria patients from southern China by polymerase chain reaction with allele 
      sequence-specific primers. The antibody and cellular response against PfCP-2.9 or 
      its components were measured by enzyme-linked immunosorbent assay and T 
      lymphocyte proliferation assay. RESULTS: In clinical subjects, the anti-PfCP-2.9 
      antibody response was likely suppressed by HLA-DR6 alleles, which was consistent 
      with the T lymphocyte proliferation assay. Nevertheless, HLA-DR7 positively 
      correlated with antibody responses in naturally infected individuals while DR8 
      correlated with weaker antibody responses for all the three recombinant proteins. 
      Moreover, parasitemia was significantly lower in samples with higher antibody 
      levels against PfCP-2.9 or rMSP1-19, but not for rAMA-1(III). CONCLUSION: These 
      data suggest that antibody responses against PfCP-2.9, AMA-1(III), or MSP1-19 
      elicited by vaccine formulation or natural infection are controlled by different 
      HLA-II alleles. Moreover, the antibody response to MSP1-19 contributed more to 
      protection immunity than AMA-1(III).
FAU - Zhang, Qingfeng
AU  - Zhang Q
AD  - Department of Pathogenic Biology and State Key Laboratory of Medical Immunology, 
      Second Military Medical University, Shanghai, China.
FAU - Xue, Xiangyang
AU  - Xue X
FAU - Xu, Xindong
AU  - Xu X
FAU - Wang, Cuiping
AU  - Wang C
FAU - Chang, Wenjun
AU  - Chang W
FAU - Pan, Weiqing
AU  - Pan W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090227
PL  - Netherlands
TA  - J Clin Immunol
JT  - Journal of clinical immunology
JID - 8102137
RN  - 0 (Antibodies, Protozoan)
RN  - 0 (Antigens, Protozoan)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Malaria Vaccines)
RN  - 0 (Membrane Proteins)
RN  - 0 (Merozoite Surface Protein 1)
RN  - 0 (PfCP2.9 vaccine)
RN  - 0 (Protozoan Proteins)
RN  - 0 (Vaccines, Synthetic)
RN  - 0 (apical membrane antigen I, Plasmodium)
SB  - IM
MH  - Alleles
MH  - Animals
MH  - Antibodies, Protozoan/blood/*genetics
MH  - Antibody Formation/genetics
MH  - Antigens, Protozoan/immunology
MH  - Clinical Trials, Phase I as Topic
MH  - Genotype
MH  - HLA-DR Antigens/*genetics/immunology
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Malaria Vaccines/administration & dosage/*immunology
MH  - Malaria, Falciparum/*immunology/prevention & control
MH  - Membrane Proteins/immunology
MH  - Merozoite Surface Protein 1/immunology
MH  - Plasmodium falciparum/*immunology
MH  - Protozoan Proteins/immunology
MH  - Randomized Controlled Trials as Topic
MH  - Vaccines, Synthetic/administration & dosage/immunology
EDAT- 2009/02/28 09:00
MHDA- 2009/09/11 06:00
CRDT- 2009/02/28 09:00
PHST- 2008/11/24 00:00 [received]
PHST- 2009/02/11 00:00 [accepted]
PHST- 2009/02/28 09:00 [entrez]
PHST- 2009/02/28 09:00 [pubmed]
PHST- 2009/09/11 06:00 [medline]
AID - 10.1007/s10875-009-9281-0 [doi]
PST - ppublish
SO  - J Clin Immunol. 2009 Jul;29(4):454-60. doi: 10.1007/s10875-009-9281-0. Epub 2009 
      Feb 27.